Recognizes a (pre)melanosomal 100+7kD antigen (glycoprotein). Reacts with melanomas, clear cells sarcomas (melanoma of soft tissue), nevocellular nevi and normal melanocytes. Except for one case of non-Hodgkin’s lymphoma in which macrophages were positive, no reactions with other tumors or tissues have been observed.
The clone number has been updated from (3F272) to (NKI/beteb) both clone numbers name the same antibody clone.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-Fr: 1/5 - 1/20. Formalin fixation and embedding in paraffin may affect the reactivity of the antibody.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity.
Preferentially expressed in melanomas. Some expression was found in dysplastic nevi. Not found in normal tissues nor in carcinomas. Normally expressed at low levels in quiescent adult melanocytes but overexpressed by proliferating neonatal melanocytes and during tumor growth.
Belongs to the PMEL/NMB family. Contains 1 PKD domain.
The RPT domain is essential for the generation of the fibrillar matrix of melanosomes. The lumenal domain is necessary for correct processing and trafficking to melanosomes.
A small amount of P1/P100 (major form) undergoes glycosylation to yield P2/P120 (minor form). P2 is cleaved by a furin-like proprotein convertase (PC) in a pH-dependent manner in a post-Golgi, prelysosomal compartment into two disulfide-linked subunits: a large lumenal subunit, M-alpha/ME20-S, and an integral membrane subunit, M-beta. Despite cleavage, only a small fraction of M-alpha is secreted, whereas most M-alpha and M-beta remain associated with each other intracellularly. M-alpha is further processed to M-alpha N and M-alpha C. M-alpha C further undergoes processing to yield M-alpha C1 and M-alpha C3 (M-alpha C2 in the case of PMEL17-is or PMEL17-ls). Formation of intralumenal fibrils in the melanosomes requires the formation of M-alpha that becomes incorporated into the fibrils. Stage II melanosomes harbor only Golgi-modified Pmel17 fragments that are derived from M-alpha and that bear sialylated O-linked oligosaccharides. N-glycosylated. O-glycosylated; contains sialic acid.
Secreted and Endoplasmic reticulum membrane. Golgi apparatus. Melanosome. Endosome > multivesicular body. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Localizes predominantly to intralumenal vesicles (ILVs) within multivesicular bodies. Associates with ILVs found within the lumen of premelanosomes and melanosomes and particularly in compartments that serve as precursors to the striated stage II premelanosomes.